Please login to the form below

Not currently logged in
Email:
Password:

Ex J&J VP joins board of Immune

Cameron Durrant also has senior experience at Pharmacia
cameron durrant immune

Immune Pharmaceuticals has added veteran pharma experience to its board with the appointment of Cameron Durrant.

Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson & Johnson and VP, Pharmacia until its acquisition by Pfizer.

His other experience includes serving as CEO of PediatRx and CEO of PediaMed Pharmaceuticals as part of a career in pharma that began at Merck & Co.

Dr Daniel Teper, Immune's chairman and CEO, commented: "I have been privileged to work with Cameron in several of his leadership roles at GSK, Pharmacia, J&J and PediaMed.

“His entrepreneurial drive along with the discipline acquired at leading companies and his extensive board experience at public and private companies will be a strong asset as Immune expands its clinical development and commercialisation activities."

Immune specialises in developing antibodies to treat patients with inflammatory diseases and cancer. Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.

21st July 2014

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Main image1
Global leaders in digital channels
Exploring why UK field teams are global leaders in digital channels is key to better understanding the changes in omnichannel engagement...
Kate Shaw reflects on Innovative Trials' first US office openings
On Thanksgiving, Kate Shaw, Founder and CEO of Innovative Trials, reflects on the company first US office opening...
Meeting1
Reimagining strategy development for a hybrid workforce
By Janice MacLennan...